Clinical-stage biotechnology company Cynata Therapeutics (ASX: CYP) has appointed experienced biopharmaceutical executive Dr Mathias Kroll to the newly created position of Chief Business Officer, commencing in mid-April.
Dr Kroll joins Cynata from QIMR Berghofer Medical Research Institute, where he has been Chief Commercial Officer since 2019. During his career of over 25 years, he has held leadership positions in companies of varying sizes, including three of the world’s largest multinationals (Bayer, Sanofi-Aventis and GlaxoSmithKline). He has also led a European biotechnology company as CEO. Between his academic and industry roles, he has been based in nine countries on four continents, showcasing his versatility and in-depth knowledge of the sector at a global level.
In his early career, Dr Kroll worked at a top tier global consultancy group, then moved into the pharmaceutical industry as research group leader, and subsequently marketing manager in charge of a large product franchise.
For the past two decades, he has focussed on corporate and business development. He has a strong track record in establishing and extracting value from partnerships between companies, investors, and other stakeholders, to fund the development and commercialisation of biopharmaceutical products. He has successfully concluded numerous international deals, across all stages of the pharmaceutical value chain, some of which have exceeded a billion dollars in value. Many of his deals were driven by matching specialised manufacturing capacity and capability with innovative therapies.
Dr Kroll obtained Master of Science (MSc) equivalent honours degrees in chemistry and biology, following university studies in Germany, the United States, and France. He was later awarded a PhD in immunology for his thesis at the Pasteur Institute in France, and an MBA from the International Institute for Management Development (IMD) in Switzerland. He has also completed training in patent law and is a graduate of the Australian Institute of Company Directors.
“I am thrilled to join Cynata as Chief Business Officer, with responsibility for business development, finance, and investor relations. Cynata offers a groundbreaking solution to the challenge of producing high-quality regenerative cell therapy products at scale and in a consistent way,” Dr Kroll said.
“With its unique technology, Cynata is well positioned to catalyse the transformation of regenerative cell therapies from relatively isolated, individual applications into universally accessible therapies which can be manufactured at scale to reach patients worldwide.
“In addition, the current advances in Cynata’s own product development pipeline boost the company’s potential to originate novel therapies in areas of high need. My objective is to establish the partnerships that will realise the full potential of both Cynata’s core technology and candidate products.”
